Memando (Memantine Hydrochloride)

Memantine acts as an uncompetitive antagonist at the NMDA receptor’s phencyclidine site. By limiting excessive calcium entry caused by prolonged glutamate activation, it reduces excitotoxic neuronal damage, thereby supporting synaptic function and slowing neurodegeneration associated with Alzheimer’s disease.

The dosing regimen for Memando is individualized and set by the prescribing clinician based on the patient’s condition, tolerability, and renal function. Healthcare professionals typically start with a low dose and may titrate upward to a target dose as tolerated, following the product’s prescribing information.

Memando should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Limited clinical data are available, so clinicians must evaluate each case carefully and discuss possible risks with the patient.

To order Memando, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative for Alzheimer’s disease is the acetylcholinesterase inhibitor class (e.g., donepezil). While both aim to improve cognition, memantine works by modulating glutamatergic activity, whereas acetylcholinesterase inhibitors increase acetylcholine levels. Memantine is often preferred for moderate to severe disease and may be combined with an acetylcholinesterase inhibitor for additive benefit.

Memando tablets should be stored at ambient temperature below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in a refrigerator or freezer, and keep out of reach of children.

Memando is taken orally as a tablet. The tablet should be swallowed whole with a glass of water and can be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious adverse reactions to monitor include seizures, severe allergic responses such as rash or angioedema, Stevens‑Johnson syndrome or toxic epidermal necrolysis, and hepatic dysfunction indicated by elevated liver enzymes. Prompt medical attention is required if any of these events occur.

Memando is contraindicated in individuals with known hypersensitivity to memantine or any of its excipients. It should also be avoided in patients with severe renal impairment unless dose adjustments are made, and it is not recommended for use together with other NMDA antagonists.